A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Clinical trial NCT05456191 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05456191
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-21
- Primary completion
- 2025-05-15
- Enrollment
- 568
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.